# AURELIA (NCT00976911)

> AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

No report yet. It can be ordered.

- Drugs tested: bevacizumab
- Indication: platinum-resistant recurrent ovarian cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00976911
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Ovarian Cancer
- Interventions: Bevacizumab; liposomal doxorubicin; paclitaxel; topotecan
- Enrollment: 361
- Primary outcome: Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011)
- Primary outcome: Progression Free Survival (PFS; Data Cutoff 14 November 2011)

## Indexed commentary on AURELIA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 20 YouTube videos
- 11 posts on X
- 10 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=aurelia-nct00976911

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00976911", "email": "<work email>"}; the inbox owner confirms by the emailed link.